Literature DB >> 22166852

Plasma noradrenaline and state anxiety levels predict placebo response in learned immunosuppression.

K Ober1, S Benson, M Vogelsang, A Bylica, D Günther, O Witzke, A Kribben, H Engler, M Schedlowski.   

Abstract

Large interindividual differences exist in the presence and extent of placebo responses in both experimental and clinical studies, but little is known about possible predictors of these responses. We employed a behaviorally conditioned immunosuppression paradigm in healthy men to analyze predictors of learned placebo responses. During acquisition, the subjects received either the immunosuppressant cyclosporin A (n = 32) or a placebo (n = 14) (unconditioned stimuli (US)) together with a novel-tasting drink (conditioned stimulus (CS)). During evocation, the subjects were reexposed to the CS alone. In responders (n = 15), the CS alone caused a significant inhibition of interleukin (IL)-2 production by anti-CD3-stimulated peripheral blood T cells, closely mimicking the drug effect. Nonresponders (n = 17) did not show responses different from those of the controls. Multiple-regression analyses showed that baseline IL-2, plasma noradrenaline, and state anxiety predicted nearly 60% of the variance in the conditioned IL-2 response. These data provide first evidence for putative biological and psychological predictors of learned placebo responses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22166852     DOI: 10.1038/clpt.2011.214

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

Review 1.  The placebo response in medicine: minimize, maximize or personalize?

Authors:  Paul Enck; Ulrike Bingel; Manfred Schedlowski; Winfried Rief
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

2.  Plasma cortisol response cannot be classically conditioned in a taste-endocrine paradigm in humans.

Authors:  Liubov Petrakova; Karoline Boy; Marisa Kügler; Sven Benson; Harald Engler; Lars Möller; Manfred Schedlowski
Journal:  Psychopharmacology (Berl)       Date:  2017-08-13       Impact factor: 4.530

Review 3.  The neuroscience of placebo effects: connecting context, learning and health.

Authors:  Tor D Wager; Lauren Y Atlas
Journal:  Nat Rev Neurosci       Date:  2015-07       Impact factor: 34.870

Review 4.  Learned immunosuppression: extinction, renewal, and the challenge of reconsolidation.

Authors:  Martin Hadamitzky; Harald Engler; Manfred Schedlowski
Journal:  J Neuroimmune Pharmacol       Date:  2012-07-13       Impact factor: 4.147

Review 5.  Prediction of placebo responses: a systematic review of the literature.

Authors:  Bjoern Horing; Katja Weimer; Eric R Muth; Paul Enck
Journal:  Front Psychol       Date:  2014-10-01

6.  Placebo effects on the immune response in humans: the role of learning and expectation.

Authors:  Antje Albring; Laura Wendt; Sven Benson; Oliver Witzke; Andreas Kribben; Harald Engler; Manfred Schedlowski
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

Review 7.  Placebo analgesia: psychological and neurobiological mechanisms.

Authors:  Luana Colloca; Regine Klinger; Herta Flor; Ulrike Bingel
Journal:  Pain       Date:  2013-02-13       Impact factor: 7.926

8.  Cognitive factors mediate placebo responses in patients with house dust mite allergy.

Authors:  Sabine Vits; Elvir Cesko; Sven Benson; Annika Rueckert; Uwe Hillen; Dirk Schadendorf; Manfred Schedlowski
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

9.  Catechol-O-methyltransferase Val158Met polymorphism is associated with somatosensory amplification and nocebo responses.

Authors:  Laura Wendt; Antje Albring; Sven Benson; Harald Engler; Andrea Engler; Anke Hinney; Winfried Rief; Oliver Witzke; Manfred Schedlowski
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

10.  Nocebo and pain: An overview of the psychoneurobiological mechanisms.

Authors:  Maxie Blasini; Nicole Corsi; Regine Klinger; Luana Colloca
Journal:  Pain Rep       Date:  2017 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.